Learn More
OBJECTIVES Cognitive comorbidity at epilepsy onset reflects disease severity and provides a baseline estimate of reserve capacities with regard to the effects of epilepsy and its treatment. Given the high incidence of epilepsy at an older age, this study analyzed objective and subjective cognition as well as quality of life in elderly patients with(More)
This prospective, multicenter, non-interventional surveillance study (ZADE study) explored seizure outcome and tolerability of adjunctive treatment with zonisamide (ZNS) in a non-selected sample of patients with partial-onset seizures in everyday clinical practice. Changes in quality of life (QOL) and health status were also recorded. Clinical status was(More)
OBJECT Resective surgery is a safe and effective treatment of drug-resistant epilepsy. If surgery has failed reoperation after careful re-evaluation may be a reasonable option. This study was to summarise the risks and benefits of reoperation in patients with epilepsy. METHODS This is a retrospective single centre study comprising clinical data, long-term(More)
Cognitive side effects of antiepileptic drugs are common and can negatively affect tolerability, compliance, and long-term retention of the treatment. Furthermore, adverse cognitive effects of pharmacotherapy significantly affect everyday functioning and quality of life. Consequently, preservation of cognitive functions is an important aspect of epilepsy(More)
OBJECTIVE Limbic encephalitis (LE) is an autoimmune mediated disease leading to temporal lobe epilepsy, mnestic and psychiatric symptoms. In recent years, several LE subforms defined by serum antibody findings have been described. MRI usually shows volume changes of the amygdala and hippocampus. However, studies quantifying longitudinal volume changes in(More)
This open-label, non-interventional, controlled surveillance study evaluated the cognitive outcome of patients administered levetiracetam (LEV) or carbamazepine (CBZ) monotherapy as primary treatment or as substitution for previous treatment. Executive functions, verbal memory, and subjective ratings were assessed before and 6 months after initiation of LEV(More)
The aim of our study was to assess cognition in newly diagnosed and untreated patients with epilepsy in order to determine the prevalence and the determinants of cognitive deficits at this early stage of the disease. A total of 247 untreated patients with newly diagnosed epilepsy underwent a brief test battery focusing on attention and executive functions(More)
Objective and subjective cognitive measures were evaluated in 401 patients before and 3 and 6 months after introducing levetiracetam (LEV). Initially, cognitive impairment was indicated in 37-44% of the patients, and subjective impairments in 32-67%. With LEV, 87% of untreated patients changed to monotherapy, and 94% changed from mono- to polytherapy. The(More)
In order to understand cognitive impairment associated with epilepsy, it is essential to appreciate that independent static and dynamic factors affect brain function in this disease. Whereas morphological lesions or structural changes are associated with more or less irreversible deficits, epileptic activity, seizures, and the treatment of epilepsy can(More)